Abeona Q2 ZEVASKYN revenue up 31% QoQ to $11.4M; net loss widens to $20.2M

ABEONA THERAPEUTICS INC.

2026-Q2 EPS reported -$0.66 revenue$20,100,000

ZEVASKYN net revenue $11.4M in Q2 2026, up 31% QoQ from $8.7M in Q1; revenue recognized for 4 of 5 treated patients
Net loss $(20.2)M ($0.35/share) vs $(17.1)M ($0.30/share) in Q1; cash $146.8M at June 30, down from $191.4M at Dec 31
QTC network expanded to 7 sites; CHOP, NewYork-Presbyterian/Columbia activated in Q2, Cincinnati Children's in Q3
CMS granted NTAP status for ZEVASKYN effective Oct 1, 2026, supporting hospital adoption and Medicare access
R&D expenses fell to $5.0M from $9.6M (Q1 included $7.0M one-time ABO-701 in-licensing cost); SG&A $15.8M vs $19.5M

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.